Ibrahim Etedal Ahmed A, Abdalla Balla Elhardallo Wadia, Hussien Mohamed Ahmed Khabab Abbasher, Abdalla Omer Mohammed E, Mahmmoud Fadelallah Eljack Mohammed
Faculty of Medicine, Al-Neelain University.
Faculty of Medicine, University of Khartoum, Khartoum.
Ann Med Surg (Lond). 2023 Mar 9;85(3):373-377. doi: 10.1097/MS9.0000000000000093. eCollection 2023 Mar.
Topiramate is an antiepileptic medication originally and one of the first-line drugs for migraine prophylaxis. Herein, we aimed to assess the outcome of topiramate in migraine prophylaxis by evaluating the reduction in frequency and/or severity of attacks and addressing the most common adverse effects associated with it.
A descriptive, prospective hospital-based study was conducted at Ibrahim Malik Hospital, National Center of Neurological Disease and Sciences from October 2018 to May 2019. A comprehensive, structural, close-ended questionnaire was used to collect data on demographics, clinical, risk factors, treatment, side effects, and outcome.
This study covered 32 study participants; the mean age was 33±10 years, with a female predominance of 27 (84%). Nearly, half of them 15 (47%) migraine triggered by weather changes, and 13 (41%) had menstruation. About 17 (53%) was suffering from headache more than 24 months and most of them 26 (81%) used over-the-counter medications for acute pain headache. The mean frequency of attacks per month was reduced from 6.1 baselines to 3.2, in the severity means was 6.9 turns to 5. Reduction in frequency of attacks there was significant in both number and severity (<0.001) with no significant difference in 50 and 100 mg doses. Concerning adverse effects, 5 (15.6%) did not complain of any, more than a third 12 (38%) experienced weight loss, 7 (22%) both abdominal/gastrointestinal symptoms and dizziness, 5 (16%) mood changes, 4 (13%) both paresthesia and decreased memory, 3 (9%) both anorexia and sleepiness.
Topiramate is effective in reducing headache frequency and reasonably well tolerated in adult Sudanese patients with episodic migraine. This may provide good evidence to support its use in routine clinical management.
托吡酯是一种抗癫痫药物，最初是偏头痛预防的一线药物之一。在此，我们旨在通过评估发作频率和/或严重程度的降低情况以及解决与之相关的最常见不良反应，来评估托吡酯在偏头痛预防中的效果。
2018年10月至2019年5月，在国家神经疾病与科学中心的易卜拉欣·马利克医院进行了一项描述性、前瞻性的基于医院的研究。使用一份全面、结构化的封闭式问卷收集有关人口统计学、临床、危险因素、治疗、副作用和结果的数据。
本研究涵盖32名研究参与者；平均年龄为33±10岁，女性占主导，有27名（84%）。其中近一半，即15名（47%）偏头痛由天气变化引发，13名（41%）与月经有关。约17名（53%）头痛超过24个月，其中大多数，即26名（81%）使用非处方药物治疗急性疼痛性头痛。每月发作的平均频率从基线时的6.1次降至3.2次，严重程度的平均值从6.9降至5。发作频率在数量和严重程度上均显著降低（<0.001），50毫克和100毫克剂量之间无显著差异。关于不良反应，5名（15.6%）未抱怨任何不良反应，超过三分之一，即12名（38%）出现体重减轻，7名（22%）同时出现腹部/胃肠道症状和头晕，5名（16%）出现情绪变化，4名（13%）同时出现感觉异常和记忆力下降，3名（9%）同时出现厌食和嗜睡。
托吡酯对减少成年苏丹发作性偏头痛患者的头痛频率有效，且耐受性较好。这可能为支持其在常规临床管理中的应用提供有力证据。
